financetom
Business
financetom
/
Business
/
Automatic Data Processing's Fiscal Q3 Adjusted Earnings, Revenue Increase; Fiscal 2024 Outlook Reiterated
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Automatic Data Processing's Fiscal Q3 Adjusted Earnings, Revenue Increase; Fiscal 2024 Outlook Reiterated
May 1, 2024 4:59 AM

07:32 AM EDT, 05/01/2024 (MT Newswires) -- Automatic Data Processing ( ADP ) reported fiscal Q3 adjusted earnings Wednesday of $2.88 per diluted share, up from $2.52 a year earlier.

Analysts polled by Capital IQ expected $2.78.

Revenue for the quarter ended March 31 was $5.25 billion, up from $4.93 billion a year earlier.

Analysts surveyed by Capital IQ expected $5.23 billion.

The company said it continues to expect fiscal 2024 adjusted EPS to grow 10% to 12% and revenue to grow 6% to 7%.

Price: 239.95, Change: -1.94, Percent Change: -0.80

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
United States Steel says Nippon Steel deal expected to close later this year
United States Steel says Nippon Steel deal expected to close later this year
Mar 15, 2024
March 15 (Reuters) - United States Steel Corp ( X ) said in a regulatory filing on Friday that agreement with Nippon Steel Corporation And Nippon Steel North America Inc expected to close later this year. ...
Neurocrine Biosciences Insider Sold Shares Worth $420,419, According to a Recent SEC Filing
Neurocrine Biosciences Insider Sold Shares Worth $420,419, According to a Recent SEC Filing
Mar 15, 2024
05:21 PM EDT, 03/15/2024 (MT Newswires) -- Ingrid Delaet, Chief Regulatory Officer, on March 13, 2024, sold 3,000 shares in Neurocrine Biosciences ( NBIX ) for $420,419. Following the Form 4 filing with the SEC, Delaet has control over a total of 7,507 shares of the company, with 7,507 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/914475/000091447524000090/xslF345X03/wk-form4_1710537319.xml ...
US FDA panel votes in favor of expanded use of Bristol Myers' CAR-T therapy
US FDA panel votes in favor of expanded use of Bristol Myers' CAR-T therapy
Mar 15, 2024
March 15 (Reuters) - Advisers to the U.S. Food and Drug Administration on Friday voted in favor of allowing the use of Bristol Myers Squibb's ( BMY ) cell therapy as an earlier treatment for a type of blood cancer. The panel voted 8-3 in favor that benefits of Bristol's Abecma outweighed the risks of the therapy when given as...
Microstrategy Insider Sold Shares Worth $2,551,757, According to a Recent SEC Filing
Microstrategy Insider Sold Shares Worth $2,551,757, According to a Recent SEC Filing
Mar 15, 2024
05:15 PM EDT, 03/15/2024 (MT Newswires) -- Michael J Saylor, 10% Owner, Director, Executive Chairman, on March 14, 2024, sold 1,508 shares in Microstrategy ( MSTR ) for $2,551,757. Following the Form 4 filing with the SEC, Saylor has control over a total of 200 shares of the company, with 200 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1050446/000095017024032301/xslF345X03/ownership.xml Price: 1750, Change:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved